Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl] oxy}- 6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

Journal of Medicinal Chemistry

Volumn 52, Issue 3, 2009, Pages 637-645

  Thompson, Andrew M ^a   Blaser, Adrian ^a   Anderson, Robert F ^a,b   Shinde, Sujata S ^a,b   Franzblau, Scott G ^c   Ma, Zhenkun ^d   Denny, William A ^a   Palmer, Brian D ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; OXAZINE DERIVATIVE; THIAZINE DERIVATIVE; TUBERCULOSTATIC AGENT; NITROIMIDAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; BACTERIAL GROWTH; CELL VIABILITY; CHEMICAL REACTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYCLIC POTENTIOMETRY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRIC POTENTIAL; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REDUCTION; ANIMAL; CERCOPITHECUS; CHEMISTRY; DRUG EFFECT; OXIDATION REDUCTION REACTION; SYNTHESIS; VERO CELL;

ANIMALS; ANTITUBERCULAR AGENTS; CERCOPITHECUS AETHIOPS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZINES; OXIDATION-REDUCTION; VERO CELLS;

EID: 61449105900     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801087e     Document Type: Article

References (38)

1. Tomioka, H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr. Pharm. Des. 2006, 12, 4047-4070.
2. Bhowruth, V.; Dover, L. G.; Besra, G. S. Tuberculosis chemotherapy: recent developments and future perspectives. Prog. Med. Chem. 2007, 45, 169-203.
3. Laurenzi, M.; Ginsberg, A.; Spigelman, M. Challenges associated with current and future TB treatment. Infect.Disord-Drug Targets 2007, 7, 105-119.
4. Lenaerts, A. J.; Gruppo, V.; Marietta, K. S.; Johnson, C. M.; Driscoll, D. K.; Tompkins, N. M.; Rose, J. D.; Reynolds, R. C.; Orme, I. M. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 2005, 49, 2294-2301.
5. Nuermberger, E.; Rosenthal, I.; Tyagi, S.; Williams, K. N.; Almeida, D.; Peloquin, C. A.; Bishai, W. R.; Grosset, J. H. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2006, 50, 2621-2625.
6. Tyagi, S.; Nuermberger, E.; Yoshimatsu, T.; Williams, K.; Rosenthal, I.; Lounis, N.; Bishai, W.; Grosset, J. Bacteriocidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Anti- microb. Agents Chemother. 2005, 49, 2289-2293.
7. Hu, Y.; Coates, A. R. M.; Mitchison, D. A. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2008, 12, 69-73.
8. Nuermberger, E.; Tyagi, S.; Tasneen, R.; Williams, K. N.; Almeida, D.; Rosenthal, I.; Grosset, J. H. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazi- namide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2008, 52, 1522-1524.
9. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Krelswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405, 962-966.
10. Manjunatha, U. H.; Boshoff, H.; Dowd, C. S.; Zhang, L.; Albert, T. J.; Norton, J. E.; Daniels, L.; Dick, T.; Pang, S. S.; Barry, C. E. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 431-436.
11. Yanez, C.; Bollo, S.; Nunez-Vergara, L. J.; Squella, J. A. Voltammetric determination of nitroimidazopyran drug candidate for the treatment of tuberculosis. Anal. Lett. 2001, 34, 2335-2348.
12. Wardman, P.; Clarke, E. D. One-electron reduction potentials of substituted nitroimidazoles measured by pulse radiolysis. J. Chem. Soc., Faraday Trans. 1 1976, 72, 1377-1390.
13. Bollo, S.; Nunez-Vergara, L. J.; Squella, J. A. Cyclic voltammetric determination of free radical species from nitroimidazopyran: a new antituberculosis agent. J. Electroanal. Chem. 2004, 562, 9-14.
14. Barry, C. E.; Boshoff, H. I. M.; Dowd, C. S. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. 2004, 10, 3239-3262.
15. Baker, W. R.; Shaopei, C.; Keeler, E. L. Nitro-[2,1-b]imidazopyran Compounds and Antibacterial Uses Thereof. U.S. Patent 6,087,358, 2000.
16. Li, X.; Manjunatha, U. H.; Goodwin, M. B.; Knox, J. E.; Lipinski, C. A.; Keller, T. H.; Barry, C. E.; Dowd, C. S. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4- (trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1- b][1,3]oxazines, analogues of PA-824. Bioorg. Med. Chem. Lett. 2008, 18, 2256-2262.
17. Nagarajan, K.; Shankar, R. G.; Rajappa, S.; Shenoy, S. J.; Costa- Pereira, R. Nitroimidazoles. XXI. 2,3-Dihydro-6-nitroimidazo[2,1- b]oxazoles with antitubercular activity. Eur. J. Med. Chem. 1989, 24, 631-633.
18. Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. OPC-67683, a nitro-dihydro- imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006, 3, 2131-2134.
19. Orita, A.; Miwa, K.; Uehara, G.; Otera, J. Integration of solventless reaction in a multi-step process: application to an efficient synthesis of PA-824. Adv. Synth. Catal. 2007, 349, 2136-2134.
20. Goto, F.; Takemura, N.; Otani, T.; Hasegawa, T.; Tsubouchi, H.; Utsumi, N.; Fujita, S.; Kuroda, H.; Shitsuta, T.; Sasaki, H. EP 1553088 A1, 2005.
21. Koehler, F. Reaction of thiophenols with 2,5-dibromo-4-nitroimidazole. J. Prakt. Chem. 1963, 21, 50-52.
22. Horning, D. E.; Kavadias, G.; Muchowski, J. M. Tetrahydropyranyl protecting group. II. 3-Bromo-2-(tetrahydropyran)-2-yloxy)-propene, a masked acetonyl bromide. Can. J. Chem. 1970, 48, 975-982.
23. Janssen, J. W. A. M.; Koeners, H. J.; Kruse, C. G.; Habraken, C. L. Pyrazoles. XII. The preparation of 3(5)-nitropyrazoles by thermal rearrangement of A-nitropyrazoles. J. Org. Chem. 1973, 38, 1777-1872.
24. Janssen, J. W. A. M.; Kruse, C. G.; Koeners, H. J.; Habraken, C. L. Pyrazoles. XIII. Ionisation constants and UV spectra of mono- and dinitropyrazoles (1,2). J. Heterocycl. Chem. 1973, 10, 1055-1058.
25. Sehgal, R. K.; Webb, M. W.; Agrawal, K. C. Potential radiosensitizing agents. 2. Synthesis and biological activity of derivatives of dini- troimidazole with oxiranes. J. Med. Chem. 1981, 24, 601-604.
26. Cativiela, C.; Serrano, J. L.; Zurbano, M. M. Synthesis of 3-substituted pentane-2,4-diones: valuable intermediates for liquid crystals. J. Org. Chem. 1995, 60, 3074-3083.
27. Perevalov, V. P.; Baryshnenkova, L. I.; Manaev, Yu. A.; Bezborodov, B. V.; Klapchuk, E. V. Reductive behavior of nitro- and dinitro-1- methylpyrazoles. Chem. Heterocycl. Compd. (Engl. Transl.) 1990, 26, 955.
28. Anderson, R. F.; Shinde, S. S.; Maroz, A.; Boyd, M.; Palmer, B. D.; Denny, W. A. Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7- dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Org. Biomol. Chem. 2008, 6, 1973-1980.
29. Wardman, P. Reduction potentials of one-electron couples involving free radicals in aqueous solution. J. Phys. Chem. Ref. Data 1989, 18, 1637-1755.
30. Jenkins, T. C.; Stratford, I. J.; Stephens, M. A. 3-Nitro-1,2,4-triazoles as hypoxia-selective agents. Anti-Cancer Drug Des. 1989, 4, 145-160.
31. Collins, L. A.; Franzblau, S. G. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. An-timicrob. Agents Chemother. 1997, 41, 1004-1009.
32. Cho, S. H.; Warit, S.; Wan, B.; Hwang, C. H.; Pauli, G. F.; Franzblau, S, G. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. An- timicrob. Agents Chemother. 2007, 51, 1380-1385.
33. Falzari, K.; Zhu, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S. G. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2005, 49, 1447-1454.
34. Sharnin, G. P.; Fassakhov, R. Kh.; Eneikina, T. A. Research on five- membered heterocycles. II. Halonitroimidazoles. Chem. Heterocycl. Compd. (Engl. Transl.) 1977, 13, 1332-1334.
35. Anderson, R. F.; Denny, W. A.; Li, W.; Packer, J. E.; Tercel, M.; Wilson, W. R. Pulse radiolysis studies on the fragmentation of arylmethyl quaternary nitrogen mustards by one-electron reduction in aqueous solution. J. Phys. Chem. A 1997, 101, 9704-9709.
36. Mulazzani, Q. G.; Venturi, M.; Hoffman, M. Z.; Rodgers, M. A. J. Interaction of formate and oxalate ions with radiation-generated radicals in aqueous solution. Methylviologen as a mechanistic probe. J. Phys. Chem. 1986, 90, 5347-5352.
37. Anderson, R. F. Electron transfer and equilibria between pyridinyl radicals and FAD. Ber. Bunsen-Ges. Phys. Chem. 1976, 80, 969-972.
38. Stekhan, E.; Kuwana, T. Spectroelectrochemical study of mediators. 1. Bipyridylium salts and their electron transfer to cytochrome C. Ber. Bunsen-Ges. Phys. Chem. 1974, 78, 253-259.